After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of Avidity Biosciences Inc is $3.74B. A total of 1.41 million shares were traded on the day, compared to an average of 1.36M shares.
In the most recent transaction, Flanagan W. Michael sold 20,000 shares of RNA for 30.13 per share on Mar 11 ’25. After the transaction, the Chief Scientific Officer now owns 91,975 company shares. In a previous transaction on Mar 11 ’25, WILLIAM MICHAEL FLANAGAN bought 20,000 shares at 30.04 per share.
Among the insiders who sold shares, Gallagher Kathleen P. disposed of 5,875 shares on Mar 03 ’25 at a per-share price of $29.41. This resulted in the Chief Program Officer holding 50,554 shares of RNA after the transaction. In another insider transaction, Gallagher Kathleen P. sold 5,875 shares at $32.16 per share on Feb 03 ’25. Company shares held by the Chief Program Officer now total 50,554.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, RNA has a high of $56.00 and a low of $21.56.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. RNA’s latest balance sheet shows that the firm has $405.54M in Cash & Short Term Investments as of fiscal 2021. There were $11.73M in debt and $29.66M in liabilities at the time. Its Book Value Per Share was $11.89, while its Total Shareholder’s Equity was $381.43M.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RNA is Buy with a score of 4.86.
